Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy

Stock Information for Sonnet BioTherapeutics Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sonnet BioTherapeutics Holdings Inc.

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
Sonnet to Present at the MedInvest Biotech & Pharma Conference
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HBI, BFIN, PBBK, SONN on Behalf of Shareholders
Sonnet Releases Virtual Investor "What This Means" Segment
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.